The French pharmaceuticals group targeted existing lenders, some of which upped their support to allow the deal to be increased.
The facility is the remnant of a Eu5bn loan taken out in 2007, containing four one-year extension options. Sanofi signed the previous extension at Eu3.7bn in January.The margin ...
Please take a trial or subscribe to access this content.
Contact Mark Goodes to discuss your access: firstname.lastname@example.org